Table 1 Baseline characteristics of patients in the training and validation cohorts
All cohort | Training cohort | Validation cohort | ||
|---|---|---|---|---|
n = 3528 | n = 2469 | n = 1059 | ||
Characteristic | N (%) | N (%) | N (%) | P value |
Sex | 0.941 | |||
Female | 1694(48.0) | 1184(48.0) | 510(48.2) | |
Male | 1834(52.0) | 1285(52.0) | 549(51.8) | |
Age, years | 0.880 | |||
> 35 | 3159(89.5) | 2209(89.5) | 950(89.7) | |
≤ 35 | 369(10.5) | 260(10.5) | 109(10.3) | |
Race | 0.798 | |||
Black | 553(15.7) | 392(15.9) | 161(15.2) | |
Other | 380(10.8) | 269(10.9) | 111(10.5) | |
White | 2595(73.5) | 1808(73.2) | 787(74.3) | |
Marital status | 0.097 | |||
Married | 1969(55.8) | 1355(54.9) | 614(58.0) | |
Unmarried/NOS | 1559(44.2) | 1114(45.1) | 445(42.0) | |
Tumor site | 0.975 | |||
Left | 1912(54.2) | 1339(54.2) | 573(54.1) | |
Right | 1616(45.8) | 1130(45.8) | 486(45.9) | |
Grade | 0.974 | |||
Grade I | 377(10.7) | 261(10.6) | 116(11.0) | |
Grade II | 2713(76.9) | 1899(76.9) | 814(76.9) | |
Grade III | 346(9.8) | 245(9.9) | 101(9.5) | |
Grade IV | 92(2.6) | 64(2.6) | 28(2.6) | |
Tumor size (cm) | 0.149 | |||
> 5 | 1579(44.8) | 1085(43.9) | 494(46.6) | |
≤ 5 | 1949(55.2) | 1384(56.1) | 565(53.4) | |
T | 0.454 | |||
T1 | 897(25.4) | 638(25.8) | 259(24.4) | |
T2 | 585(16.6) | 406(16.4) | 179(16.9) | |
T3 | 1698(48.1) | 1172(47.5) | 526(49.7) | |
T4 | 348(9.9) | 253(10.2) | 95(9.0) | |
TNM | 0.636 | |||
I | 1482(42.0) | 1044(42.3) | 438(41.4) | |
II | 2046(58.0) | 1425(57.7) | 621(58.6) | |
Chemotherapy | 0.962 | |||
Yes | 763(21.6) | 535(21.7) | 228(21.5) | |
No/unknown | 2765(78.4) | 1934(78.3) | 831(78.5) | |
Survival status | 0.348 | |||
Alive | 3377(95.7) | 2369(95.9) | 1008(95.2) | |
Dead | 151(4.3) | 100(4.1) | 51(4.8) | |